Article citationsMore>>

Dudek, D., Onuma, Y., Ormiston, J.A., Thuesen, L., Miquel-Hebert, K. and Serruys, P.W. (2012) Four-Year Clinical Follow-Up of the Everolimus-Eluting Bioresorbable Vascular Scaffold in Patients with de novo Coronary Artery Disease: The ABSORB Trial. EuroIntervention, 7, 1060-1061. http://dx.doi.org/10.4244/EIJV7I9A168

has been cited by the following article:

• TITLE: Percutaneous Coronary Interventional Treatment for Coronary Artery Disease and the Role of Antiplaplatelets Therapy: A Review of the Literature

  AUTHORS: Mostafa Al Shamiri, Abdulelah F. Al Mobeirek, Hanan Albackr, Turki B. Albacker

  KEYWORDS: Percutaneous Coronary Intervention; Coronary Artery Disease; Antiplatelets; Coronary Stents; Drug Eluting Stents; Bare Metal Stents

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.5 No.5, March 21, 2014

  ABSTRACT: Uses of balloon catheters or BMS for the treatment of coronary artery lesions shows good short-term results but long-term follow up revealed restenosis in up to 20%-30% of patients. Thus new improvements to balloons and stents are always necessary to achieve the best results from percutaneous coronary intervention (PCI). Drug-eluting stents (DES) improved the principles of bare metal stents (BMS) by local drug release to inhibit neointimal growth. DES reduced the incidence of in-stent restenosis. These benefits and lower costs compared to surgical treatment make the DES an attractive alternative for the treatment of coronary artery disease. Different components of DES which include the polymers, drugs and the stents underwent progressive evolution, and these led to development of new generations of DES with variable types of drugs and polymers to fully absorbable stents. The concern of stent thrombosis still an issue and dual antiplatlets therapy (DAPT) is mandatory for variable time ranging from one month to one year. This article discusses the main available clinical trials in the developments of BMS, DES and the comparison between both with a prospective look at future technologies in the field, in addition to reviewing the current guideline in the uses of DAPT after PCI.